Literature DB >> 12777949

Antihypertensive effect of glucagon-like peptide 1 in Dahl salt-sensitive rats.

Ming Yu1, Carol Moreno, Kimberly M Hoagland, Annette Dahly, Katie Ditter, Mahesh Mistry, Richard J Roman.   

Abstract

BACKGROUND: Dahl salt-sensitive (Dahl S) rats exhibit many phenotypic traits associated with salt-sensitive hypertension in man. Specifically, they are salt-sensitive, insulin-resistant and hyperlipidemic. They also develop endothelial dysfunction, cardiac injury and glomerulosclerosis. Insulin resistance is linked to hypertension, renal and cardiac damage and endothelial dysfunction. Thus, an agent that has diuretic action and can improve insulin resistance, like recombinant glucagon-like peptide-1(7-36)amide (rGLP-1), may have an antihypertensive effect.
OBJECTIVE: To determine whether chronic administration of rGLP-1 attenuates the development of hypertension, endothelial dysfunction and/or hypertension-induced renal and cardiac end organ damage in Dahl S rats.
METHODS: Mean arterial pressure (MAP) and urinary excretion of protein and albumin were measured in Dahl S rats before and after they were fed a 8% NaCl diet and infused with rGLP-1 (1 micro g/kg per min, i.v.) or vehicle for 14 days. At the end of the study, the degree of renal and cardiac injury was histologically assessed and endothelium-dependent relaxing function was studied using aortic rings. In other rats, the effects of rGLP-1 on sodium and water balance and plasma glucose and insulin levels for the first 3 days following a step change in sodium intake from a 0.1% NaCl diet to 7.5 mEq/day were determined.
RESULTS: rGLP-1 significantly attenuated the development of hypertension in Dahl S rats (136 +/- 7 versus 174 +/- 6 mmHg). This was associated with reduction in proteinuria (46 +/- 7 versus 128 +/- 15 mg/day) and albuminuria (46 +/- 7 versus 86 +/- 18 mg/day) and improvement of endothelial function and renal and cardiac damage. rGLP-1 markedly increased urine flow and sodium excretion for the first 3 days following elevation in sodium intake. It had no significant effects on plasma glucose and insulin concentrations.
CONCLUSION: rGLP-1 has antihypertensive and cardiac and renoprotective effects in Dahl S rats fed a high salt diet. The antihypertensive effect of rGLP-1 in Dahl S rats is due mainly to its diuretic and natriuretic effects, rather than an effect to improve insulin-resistance.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12777949     DOI: 10.1097/00004872-200306000-00012

Source DB:  PubMed          Journal:  J Hypertens        ISSN: 0263-6352            Impact factor:   4.844


  103 in total

1.  Potential role of TCF7L2 gene variants on cardiac sympathetic/parasympathetic activity.

Authors:  Virginia Boccardi; Immacolata Ambrosino; Michela Papa; Daniela Fiore; Maria Rosaria Rizzo; Giuseppe Paolisso; Michelangela Barbieri
Journal:  Eur J Hum Genet       Date:  2010-07-21       Impact factor: 4.246

Review 2.  GLP-1 Agonists and Blood Pressure: A Review of the Evidence.

Authors:  Aditya Goud; Jixin Zhong; Matthew Peters; Robert D Brook; Sanjay Rajagopalan
Journal:  Curr Hypertens Rep       Date:  2016-02       Impact factor: 5.369

Review 3.  Glucagon-like peptide 1 (GLP-1).

Authors:  T D Müller; B Finan; S R Bloom; D D'Alessio; D J Drucker; P R Flatt; A Fritsche; F Gribble; H J Grill; J F Habener; J J Holst; W Langhans; J J Meier; M A Nauck; D Perez-Tilve; A Pocai; F Reimann; D A Sandoval; T W Schwartz; R J Seeley; K Stemmer; M Tang-Christensen; S C Woods; R D DiMarchi; M H Tschöp
Journal:  Mol Metab       Date:  2019-09-30       Impact factor: 7.422

4.  A Novel GLP1 Receptor Interacting Protein ATP6ap2 Regulates Insulin Secretion in Pancreatic Beta Cells.

Authors:  Feihan F Dai; Alpana Bhattacharjee; Ying Liu; Battsetseg Batchuluun; Ming Zhang; Xinye Serena Wang; Xinyi Huang; Lemieux Luu; Dan Zhu; Herbert Gaisano; Michael B Wheeler
Journal:  J Biol Chem       Date:  2015-08-13       Impact factor: 5.157

Review 5.  Incretins and selective renal sodium-glucose co-transporter 2 inhibitors in hypertension and coronary heart disease.

Authors:  Ramiro A Sanchez; Hugo Sanabria; Cecilia de Los Santos; Agustin J Ramirez
Journal:  World J Diabetes       Date:  2015-09-10

Review 6.  Update on the treatment of type 2 diabetes mellitus.

Authors:  Juan José Marín-Peñalver; Iciar Martín-Timón; Cristina Sevillano-Collantes; Francisco Javier Del Cañizo-Gómez
Journal:  World J Diabetes       Date:  2016-09-15

Review 7.  Combination therapy with GLP-1 receptor agonist and SGLT2 inhibitor.

Authors:  Ralph A DeFronzo
Journal:  Diabetes Obes Metab       Date:  2017-06-07       Impact factor: 6.577

8.  GLP-1 at physiological concentrations recruits skeletal and cardiac muscle microvasculature in healthy humans.

Authors:  Sharmila C Subaran; Matthew A Sauder; Weidong Chai; Linda A Jahn; Dale E Fowler; Kevin W Aylor; Ananda Basu; Zhenqi Liu
Journal:  Clin Sci (Lond)       Date:  2014-08       Impact factor: 6.124

9.  The role of incretins in cardiovascular control.

Authors:  Derek D Mafong; Robert R Henry
Journal:  Curr Hypertens Rep       Date:  2009-02       Impact factor: 5.369

10.  Treatment of patients with diabetes with GLP-1 analogues or DPP-4- inhibitors: a hot topic for cardiologists?

Authors:  Thomas Jax
Journal:  Clin Res Cardiol       Date:  2008-10-13       Impact factor: 5.460

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.